Table 1.

Primary and Secondary Efficacy Variables

SOT Variable	Placebo n = 33	Ramelteon n = 33	Positive Control n = 33
ES5
Baseline	67.76 (7.247)	67.82 (9.385)	67.77 (8.147)
Change from baseline	−4.34 (2.834)	−2.70(2.829)	−40.87 (2.781)
p Value	—	0.650	< 0.001
ES6
Baseline	61.06 (13.544)	66.48 (10.102)	64.96 (12.973)
Change from Baseline	−2.35 (3.143)	−4.23 (3.128)	−41.08 (3.048)
p Value	—	0.670	< 0.001
CES
Baseline	77.61 (5.539)	78.70 (5.040)	78.36 (4.904)
Change from baseline	−2.02 (1.843)	−2.54 (1.835)	−28.60 (1.799)
p Value	—	0.837	< 0.001
Somatosensory Ratio
Baseline	0.97 (0.030)	0.97 (0.027)	0.97 (0.032)
Change from Baseline	0.00 (0.041)	0.00 (0.041)	0.03 (0.041)
p Value	—	0.960	0.567
Visual Ratio
Baseline	0.89 (0.057)	0.88 (0.070)	0.87 (0.068)
Change from baseline	−0.03 (0.029)	0.00 (0.029)	−0.26 (0.028)
p Value	—	0.439	< 0.001
Vestibular Ratio
Baseline	0.73 (0.074)	0.73 (0.096)	0.73 (0.083)
Change from baseline	−0.04 (0.032)	−0.02 (0.032)	−0.42 (0.032)
p Value	—	0.531	< 0.001
Preference Ratio
Baseline	0.96 (0.065)	0.99 (0.065)	0.99 (0.083)
Change from baseline	0.01 (0.023)	0.00 (0.023)	0.02 (0.023)
p Value	—	0.820	0.777

Baseline values are reported as mean (SD). Change from baseline values are reported as mean (SEM); p values are based on comparisons of ramelteon or positive control (zolpidem, 10 mg) vs placebo. SOT refers to Sensory Organization Test; ES5, equilibrium score for condition 5; ES6, equilibrium score for condition 6; CES, composite equilibrium score for all 6 conditions.